HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
D.S. Siegel,
K. Weisel,
A. Zahlten-Kumeli,
R. Medhekar,
S. Sapra,
B. Ding,
X. Leleu
Affiliations
D.S. Siegel
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United States
K. Weisel
Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
